Madecassoside prevents A beta(25-35)-induced inflammatory responses and autophagy in neuronal cells through the class III PI3K/Beclin-1/Bcl-2 pathway

作者：Du, Baoshun; Zhang, Zheying; Li, Na^*

来源：International Immunopharmacology, 2014, 20(1): 221-228.

DOI：10.1016/j.intimp.2014.02.036

• Madecassoside
• Autophagy
• A beta deposition
• Inflammatory responses
• PI3K/Beclin-1/Bcl-2 pathway
• Alzheimer's disease

Inflammatory responses and autophagy have been implicated in the amyloid-beta (A beta) aggregation in Alzheimer's disease (AD) due to recycling cellular waste and eliminating toxic protein aggregates. Madecassoside (Mad), a triterpenoid saponin compound, has been found to improve impaired cognitive function. However, little was known about the protection of Mad nerve cells against inflammation response and autophagy, as well as their underlying mechanism. In the present study, we investigated whether Mad could prevent A beta(25-35)-induced inflammatory responses and autophagy, as well as the possible mechanism. Transmission electron microscopy results showed that Mad could significantly reduce A beta(25-35)-induced autophagosomes in neural cells. Mad could also increase cell viability whereas decrease remarkably LDH leakage in A beta(25-35)-induced neural cells. Both ELISA assay and western blot showed that Mad attenuated inflammatory cytokines including tumor necrosis factor (TNF)-alpha, interleukin (IL)-10, IL-6 and COX-2 production. Moreover, western blot results showed that Mad could block the conversion of light chain3-I (LC3-I) to light chain3-II (LC3-II), reduce Beclin-1, whereas increase anti-apoptotic protein Bcl-2 level. The levels of Beclin-1 and hVps34 in control vector-transfected NG108-15 neural cells but not in Bcl-2 transfected NG108-15 neural cells were reduced by Mad. The levels of inflammatory cytokines including TNF-alpha and IL-6 productions decreased significantly by the treatment with Mad. These results demonstrated that Mad protected neural cells against inflammation and autophagy induced by A beta(25-35) through the class III PI3K/Beclin-1/Bcl-2 pathway. Our findings provide evidences for the beneficial effect of Mad on the treatment of AD.

• 出版日期2014-5
• 单位新乡医学院